HOME >> BIOLOGY >> NEWS
UNC to test virus treatment for recurrent head and neck cancer

Chapel Hill - The University of North Carolina at Chapel Hill School of Medicine is one of nine medical centers nationally trying to determine if injections of a genetically modified common cold virus may be an effective treatment for recurrent head and neck cancer.

Under investigation is a form of adenovirus that's modified to selectively infect and destroy tumor cells only.

Unmodified, adenoviruses can infect and multiply in both cancer and normal cells, thereby killing all cells. One of the genes that enable the virus to replicate is E1B. This gene's protein inactivates the tumor suppressor gene, p53, which normally protects the cell from adenovirus infection. "Unless p53 is inactivated, adenoviruses cannot replicate," explained Wendell G. Yarbrough, MD, assistant professor of otolaryngology/head and neck surgery at UNC-CH. "About 50% of malignant head and neck tumors are made of cells with an inactivated p53 gene. Cancer cells are the only cells in the body in which p53 has been inactivated allowing for specific killing of cancer cells by the modified virus." Adenovirus with a mutated or deleted E1B gene will not produce the protein needed to inactivate p53. This means the virus replicates only in tumor cells, not in normal ones.

"And when this virus gets in a cancer cell with inactivated p53, it replicates, makes new adenoviruses, and then as part of its normal life cycle, it lyses or kills that cell and releases viruses that can then infect adjacent cancer cells," Yarbrough said.

Yarbrough, the principal investigator for UNC in this clinical trial, said therapy using E1B-mutated adenovirus ties in with his basic research on the gene ARF, an activator of p53. "In fact, we're now combining ARF with this virus to look at the effect of this combination on tumor cells."

The researcher notes that previous studies using adenoviruses as cancer therapy have relied on viruses unable to replicate. But the modified adenovirus developed by Ony
'"/>

Contact: Leslie H. Lang
llang@med.unc.edu
919-843-9687
University of North Carolina School of Medicine
13-Mar-2001


Page: 1 2

Related biology news :

1. Pacific Northwest team unveils largest virus proteome to date
2. No role for simian virus 40 in human pleural mesotheliomas
3. Cannabis may help combat cancer-causing herpes viruses
4. Scientists find nanowires capable of detecting individual viruses
5. $7.5 Million grant to Yale researchers for role of viruses in cancer
6. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
7. Common cold virus can cause polio in mice when injected into muscles
8. Defensive action by influenza viruses demonstrated by Hebrew university researcher
9. Study of flu patients reveals virus outsmarting key drug
10. Images reveal how rotavirus - leading cause of diarrhea - enters cells
11. Bright idea could doom cancer and viruses, say Purdue scientists

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UNC test virus treatment for recurrent head and neck cancer

(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: